Prediction of an effective cervical ripenning in the induction of labour using vaginal dinoprostone.


Journal

Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288

Informations de publication

Date de publication:
26 04 2023
Historique:
received: 20 04 2022
accepted: 21 04 2023
medline: 28 4 2023
pubmed: 27 4 2023
entrez: 26 4 2023
Statut: epublish

Résumé

To develop a predictive model for successful cervical ripening in women that undergo induction of labour by means of a vaginal prostaglandin slow-release delivery system (Propess®).  Prospective observational study on 204 women that required induction of labour between February 2019 and May 2020 at "La Mancha Centro" hospital in Alcázar de San Juan, Spain. The main variable studied was effective cervical ripening (Bishop score > 6). Using multivariate analysis and binary logistic regression, we created three initial predictive models (model A: Bishop Score + Ultrasound cervical length + clinical variables (estimated fetal weight, premature rupture of membranes and body mass index)); model B: Ultrasound cervical lenght + clinical variables; and model C: Bishop score + clinical variables) to predict effective cervical ripening. All three predictive models obtained (A, B and C) presented good predictive capabilities, with an area under the ROC curve ≥ 0.76. Predictive model C, composed of the variables: gestational age (OR 1.55, 95% CI 1.18-2.03, p = 0.002), premature rupture of membranes (OR 3.21 95% CI 1.34-7.70, p = 0.09) body mass index (OR 0.93, 95% CI 0.87-0.98, p = 0.012), estimated fetal weight (OR 0.99, 95% CI 0.99-1.00, p = 0.068) and Bishop score (OR 1.49 95% CI 1.18-1.81, p = 0.001), is presented as the model of choice with an area under the ROC curve of 0.76 (95% CI 0.70-0.83, p < 0.001). A predictive model composed of the variables: gestational age, premature rupture of membranes, body mass index, estimated fetal weight and Bishop score upon admission presents good capabilities in predicting successful cervical ripening following administration of prostaglandins. This tool could be useful in making clinical decisions with regard to induction of labour.

Identifiants

pubmed: 37100837
doi: 10.1038/s41598-023-33974-7
pii: 10.1038/s41598-023-33974-7
pmc: PMC10133331
doi:

Substances chimiques

Dinoprostone K7Q1JQR04M
Prostaglandins 0

Types de publication

Observational Study Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

6855

Informations de copyright

© 2023. The Author(s).

Références

Ultrasound Obstet Gynecol. 2013 Nov;42(5):500-8
pubmed: 23533137
Obstet Gynecol. 1964 Aug;24:266-8
pubmed: 14199536
Am J Perinatol. 2013 Sep;30(8):625-30
pubmed: 23283806
Medicine (Baltimore). 2018 Nov;97(48):e13251
pubmed: 30508911
Clin Obstet Gynecol. 2006 Sep;49(3):573-84
pubmed: 16885664
Am J Obstet Gynecol. 2014 Jan;210(1):56.e1-6
pubmed: 23999422
J Midwifery Womens Health. 2013 Mar-Apr;58(2):133-44; quiz 238-9
pubmed: 23590485
Ultrasound Obstet Gynecol. 2015 Mar;45(3):358-62
pubmed: 25632014
Ultrasound Obstet Gynecol. 2002 Mar;19(3):254-7
pubmed: 11896946
J Matern Fetal Neonatal Med. 2016;29(14):2332-6
pubmed: 26515427
Obstet Gynecol. 2009 Jul;114(1):136-138
pubmed: 19546770
BJOG. 2016 Feb;123(3):346-54
pubmed: 26538408
J Obstet Gynaecol Can. 2013 Sep;35(9):840-857
pubmed: 24099451
J Matern Fetal Neonatal Med. 2010 Jun;23(6):536-40
pubmed: 19895355
Obstet Gynecol. 2009 Aug;114(2 Pt 1):261-267
pubmed: 19622986
J Obstet Gynaecol Res. 2018 Sep;44(9):1739-1746
pubmed: 29978599
Arch Gynecol Obstet. 2017 Feb;295(2):343-349
pubmed: 27928676
Med Sci Monit. 2012 Aug;18(8):CR518-522
pubmed: 22847202
Drugs. 2018 Oct;78(15):1615-1624
pubmed: 30317521
Gynecol Obstet Invest. 2009;67(2):113-7
pubmed: 18971583
Semin Perinatol. 2015 Oct;39(6):475-82
pubmed: 26341066
Obstet Gynecol. 2009 Jul;114(1):192-202
pubmed: 19546798
Cochrane Database Syst Rev. 2015 Jun 12;(6):CD010762
pubmed: 26068943
Arch Gynecol Obstet. 2012 Sep;286(3):739-53
pubmed: 22546948
Semin Perinatol. 2020 Mar;44(2):151216
pubmed: 31813539
Am J Obstet Gynecol. 2007 Aug;197(2):186-92
pubmed: 17689645

Auteurs

Nuria López Jiménez (N)

Department of Obstetrics and Gynecology, Hospital Universitario de Torrevieja, 03186, Torrevieja, Spain.

Fiamma García Sánchez (F)

Department of Obstetrics and Gynecology, Hospital General Universitario Nuestra Señora del Prado, 45600, Talavera de la Reina, Toledo, Spain.

Rafael Hernández Pailos (RH)

Department of Gynecology, Hospital Universitario Ramón y Cajal, 28034, Madrid, Spain.

Valentin Rodrigo Álvaro (V)

Department of Obstetrics and Gynecology, Hospital La Mancha Centro, 13600, Alcázar de San Juan, Ciudad Real, Spain.

Ana Pascual Pedreño (A)

Department of Obstetrics and Gynecology, Hospital La Mancha Centro, 13600, Alcázar de San Juan, Ciudad Real, Spain.

María Moreno Cid (M)

Department of Obstetrics and Gynecology, Hospital La Mancha Centro, 13600, Alcázar de San Juan, Ciudad Real, Spain.

Antonio Hernández Martínez (A)

Department of Nursing, Physiotherapy and Occupational Therapy, Faculty of Nursing, University of Castilla La Mancha IDINE, 13071, Ciudad Real, Spain. antonio.hmartinez@uclm.es.

Milagros Molina Alarcón (M)

Department of Nursing, Physiotherapy and Occupational Therapy, Faculty of Nursing, University of Castilla-La Mancha IDINE, 02001, Albacete, Spain.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH